Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 57, Issue 7, Pages 3148-3153Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm5002088
Keywords
-
Categories
Funding
- NIH [DA003910, MH083754, DA007281, GM007767]
- Ruth L. Kirschtein National Service Award NIH Training Grant [DA007267]
Ask authors/readers for more resources
We have previously described a cyclic tetrapeptide, 1, that displays mu opioid receptor (M0Pr) agonist and 6 opioid receptor (DOPr) antagonist activity, a profile associated with a reduced incidence of opioid tolerance and dependence. Like many peptides, 1 has poor bioavailability. We describe here an analogue of 1 with an added C-terminal beta-glucosylserine residue, Ser(beta-Glc)NH2, a modification that has previously been shown to improve bioavailability of opioid peptides. The resulting peptide, 4, exhibits full antinociceptive efficacy in the mouse warm water tail withdrawal assay after intraperitoneal administration with potency similar to that of morphine. Further, 4 does not give rise to acute tolerance and thus represents a promising lead for the development of opioid analgesics with reduced side effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available